1259404-17-5

Basic information

• Product Name: raceMic-Tasocitinib
• Synonyms: raceMic-Tasocitinib;racemic-tofacitinib;3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
• CAS NO: 1259404-17-5
• Molecular Formula: C16H20N6O
• Molecular Weight: 312.38
• Mol File: 1259404-17-5.mol
• Article Data: 44

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: raceMic-Tasocitinib(CAS DataBase Reference)
• NIST Chemistry Reference: raceMic-Tasocitinib(1259404-17-5)
• EPA Substance Registry System: raceMic-Tasocitinib(1259404-17-5)

Safety Data

• Hazardous Substances Data: 1259404-17-5(Hazardous Substances Data)

Upstream product

• 1228879-37-5 N,4-dimethyl-1-(phenylmethyl)-3-piperidineamine bishydrochloride 
• 1236033-21-8 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester 
• 1260614-73-0 N-methyl-N-((3S,4S)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 372-09-8 cyanoacetic acid 
• 1260590-51-9 N-methyl-N-((3R,4R)-4-methylpiperidine-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride 
• 105-56-6 ethyl 2-cyanoacetate 
• 1260590-51-9 ((3R,4R)-4-methylpiperidin-3-yl)-N-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine dihydrochloride 
• 1675248-19-7 C₁₆H₂₂N₆O₂ 
• 1675248-18-6 C₁₈H₂₅N₅O₃ 
• 56657-76-2 succinimidyl cyanoacetate 
• 477600-70-7 N-(3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine 
• 1204176-45-3 methyl-(4-methylpiperidin-3-yI)carbamate 
• 1443435-54-8 tofacitinib mono-oxalate 

Downstream Products

• 540737-29-9 tofacitinib hemi-citrate 
• 540737-29-9 Tofacitinib citrate 
• 1675248-19-7 C₁₆H₂₂N₆O₂ 
• 540737-29-9 tofacitinib citrate 

Relevant articles and documents

Short enantioselective total synthesis of (+)-tofacitinib

An enantioselective total synthesis of Tofacitinib (CP-690,550), a Janus tyrosine kinase (JAK3) specific inhibitor has been achieved from the readily available 4-piperidone. Proline catalysed hydroxylation is the key step for the synthesis of enantiopure 1-benzyl-4-methylpiperidin-3-ol.

A NOVEL CRYSTALLINE FORM OF TOFACITINIB, METHOD FOR PREPATING THEREOF

The present inventors overcome the stability of amine, dihydro, and benzoyl compound generation, which are special related substances of tofacitinib citrate, which are currently on the market. In addition, the present invention relates to a novel crystal form of tofacitinib free base with improved ease of preparation, wherein the novel crystal form of tofacitinib free base can be used as a therapeutic or prophylactic pharmaceutical composition useful in the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The present invention provides a novel crystalline form of tofacitinib free base represented by chemical formula 2.

PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME

The present invention provides a novel process for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof, which is an intermediate useful for the preparation of tofacitinib. The present invention also provides a novel intermediate used in the process, i.e., isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)carbamate dibenzoyl-L-tartrate. The present invention also provides a novel intermediate, having excellent stability, useful for the preparation of tofacitinib, i.e., (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate. In addition, the present invention provides a process for preparing tofacitinib or a pharmaceutically acceptable salt thereof using the process.